FR2287238A1 - Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents - Google Patents

Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents

Info

Publication number
FR2287238A1
FR2287238A1 FR7434368A FR7434368A FR2287238A1 FR 2287238 A1 FR2287238 A1 FR 2287238A1 FR 7434368 A FR7434368 A FR 7434368A FR 7434368 A FR7434368 A FR 7434368A FR 2287238 A1 FR2287238 A1 FR 2287238A1
Authority
FR
France
Prior art keywords
walls
brucella
covering
treated
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7434368A
Other languages
French (fr)
Other versions
FR2287238B1 (en
Inventor
Gerard Dubray
Nicole Bosseray
Michel Plommet
Jacques Dufresnoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to FR7434368A priority Critical patent/FR2287238A1/en
Publication of FR2287238A1 publication Critical patent/FR2287238A1/en
Application granted granted Critical
Publication of FR2287238B1 publication Critical patent/FR2287238B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antibrucellic vaccine consists of the covering or walls of Brucella bacterial cells, substantially free from their cytoplasmic contents. The vaccine is used to prevent brucellosis in man and animals and has the advantage of being very effective whilst enabling a distinction to be made between vaccinated animals and animals infected with Brucella, in the standard test. Cultures of Brucella, which may be of any strains of B. abortus, B. melitensis, B. suis or B. ovis, are treated mechanically to rupture the cell walls, and then treated enzymatically to eliminate the nucleic acids e.g. with desoxyribonuclease or ribonuclease. Proteins and lipids are then eliminated, esp. by boiling with aq. dodecyl sulphate. When a smooth bacteris is used, the covering or walls of the cells may also be treated with water containing a surfactant to eliminate external lipopolysaccharides. The residual material comprises a peptidoglycane structure linked covalently to polysaccharides. Vaccines in which the starting bacteris is B, abortus 99S or B. melitensis 16M are specif. claimed.
FR7434368A 1974-10-11 1974-10-11 Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents Granted FR2287238A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7434368A FR2287238A1 (en) 1974-10-11 1974-10-11 Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7434368A FR2287238A1 (en) 1974-10-11 1974-10-11 Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents

Publications (2)

Publication Number Publication Date
FR2287238A1 true FR2287238A1 (en) 1976-05-07
FR2287238B1 FR2287238B1 (en) 1978-07-28

Family

ID=9144024

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7434368A Granted FR2287238A1 (en) 1974-10-11 1974-10-11 Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents

Country Status (1)

Country Link
FR (1) FR2287238A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506615A1 (en) * 1981-06-01 1982-12-03 Merieux Inst Vaccine against brucellosis in humans - contg. phenol insoluble fraction of defatted Brucella abortus cells
FR2524315A1 (en) * 1982-04-02 1983-10-07 Merieux Inst Antigen for detecting cutaneous hypersensitivity to brucellosis - comprises the phenol-soluble fraction of delipidated Brucella abortus bacteria, esp. strain B19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2035795A1 (en) * 1969-03-31 1970-12-24 Merieux Inst Anti-brucellosis vaccine prepn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2035795A1 (en) * 1969-03-31 1970-12-24 Merieux Inst Anti-brucellosis vaccine prepn

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506615A1 (en) * 1981-06-01 1982-12-03 Merieux Inst Vaccine against brucellosis in humans - contg. phenol insoluble fraction of defatted Brucella abortus cells
FR2524315A1 (en) * 1982-04-02 1983-10-07 Merieux Inst Antigen for detecting cutaneous hypersensitivity to brucellosis - comprises the phenol-soluble fraction of delipidated Brucella abortus bacteria, esp. strain B19

Also Published As

Publication number Publication date
FR2287238B1 (en) 1978-07-28

Similar Documents

Publication Publication Date Title
DE69806408D1 (en) RECOMBINANT VACCINES CONTAINING THE IMMUNOGENIC ATTENUATED RPOS-POSITIVE PHENTOTYPE BACTERIA
IE822543L (en) Vaccines from antigenic gene products of recombinant genes
ES8706208A1 (en) Expression of immunologically reactive viral proteins.
GB1460508A (en) Cementing of wells
FR2287238A1 (en) Anti brucellosis vaccine - consisting of the covering or walls of brucella cells free from their cytoplasmic contents
ES553758A0 (en) A METHOD FOR PREPARING PROTEINS THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO VIRUSES ASSOCIATED WITH LYMPHADENOPATHY.
IT1030494B (en) DISPERSING AGENT AND PROCEDURE FOR THE DISPERSION OF SOLID PARTICLES IN AN AQUEOUS SYSTEM
DE2962920D1 (en) Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it
GB1461188A (en) Live influenza virus vaccines and preparation thereof
Anderson The effect of a sulphated polysaccharide upon the diffusion of pepsin through mucin
IT1121251B (en) PROCESS OF TRANSFORMATION OF WASTE RUBBER INTO GASEOUS AND LIQUID FUELS WITH THE METHOD OF PIROSCISSIONE
KR880007728A (en) Virus Vectors and Recombinant DNA
KR890002402A (en) Human papillomavirus type 41, its DNA and proteins encoded therefrom
JPS6465444A (en) Polycation oriented buffer and gel electrophoresis of nucleic acid using the same
CHAKRAVORTY et al. Role of sie gene in transient depression of macromolecular synthesis in phage P22-infected Salmonella typhimurium
KR880004092A (en) Gene for A-type Inclusion Body of Cellulose Virus
RU93020804A (en) METHOD OF OBTAINING BRUZELETNY ANTIGEN
Kojo Estimation of the molecular length of petite negative yeast mitochondrial DNA
GB1378406A (en) Centrifuges
SU147017A1 (en) The way to control the tightness of buildings semiconductor devices
Schablik et al. The effect of polyethylene glycol upon DNA uptake in Neurospora crassa
FR1462807A (en) Method of reinforcing large volume vessels with thin walls, in particular vessels for the fermentation or transport of beer
Yu et al. Simple and rapid procedure for detection and enzymatic analysis of plasmids.
GB1536552A (en) Method of applying a compressive force to the walls of a vessel
FR2096870A1 (en) Bivalent vaccine - for veterinary immunization against rabies and brucellosis

Legal Events

Date Code Title Description
ST Notification of lapse